Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Difetarsone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.35 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.35 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difetarsone SCHEMBL5058528 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2D6MAPTGAA | |
| Difetarsone SCHEMBL1813594 | 0.81 | ALDH1A1 (0.61) | ALDH1A1CYP1A2CYP2D6MAPTGAA | |
| SCHEMBL66153 | 0.80 | KMT2A (0.42) | ALDH1A1CYP1A2CYP2D6MAPTPRSS1 | |
| SCHEMBL1161861 | 0.63 | APP (0.55) | ALDH1A1MAPTGAAPRSS1KMT2A | |
| SCHEMBL15413903 | 0.63 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP2D6MAPTGAA | |
| SCHEMBL886902 | 0.62 | CYP2C19 (0.53) | ALDH1A1CYP2D6MAPTGAAPRSS1 | |
| SCHEMBL66154 | 0.62 | KMT2A (0.59) | ALDH1A1CYP1A2CYP2D6MAPTKMT2A | |
| Ammonia Solution, Strong SCHEMBL4445612 | 0.61 | CYP2C19 (0.36) | ALDH1A1MAPTLMNASMN1; SMN2TP53 | |
| SCHEMBL6152657 | 0.60 | MAPT (0.50) | ALDH1A1MAPTGAAPRSS1LMNA | |
| SCHEMBL3875680 | 0.60 | PRSS1 (0.84) | PRSS1LMNAF2PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993117-B2 | Devices with multiple surface functionality | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-03-31 | — | — | US | claimed |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | claimed |
| US-20120121661-A1 | DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-05-17 | — | — | US | claimed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| EP-0911031-B1 | Use of arsenic for preparing a medicament for the treatment of premenstrual syndrome | TARELLO WALTER (IT) | 2004-12-15 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0911031-A2 | Use of arsenic for preparing a medicament for the treatment of premenstrual syndrome | TARELLO, Walter (IT) | 1999-04-28 | — | — | EP | claimed |
| EP-0305968-A2 | Compositions against protozoal diseases | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1989-03-08 | — | — | EP | claimed |
| EP-4382109-A1 | USE OF A COMPOSITE MATERIAL | Heraeus Medical GmbH (DE) | 2024-06-12 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-0655971-A1 | PARTICLE BINDERS | WEYERHAEUSER COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0655970-A1 | PARTICLE BINDING TO FIBERS | WEYERHAEUSER COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
| WO-1994004352-A1 | PARTICLE BINDERS | WEYERHAEUSER COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994004351-A1 | PARTICLE BINDING TO FIBERS | WEYERHAEUSER COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
| EP-0305968-A2 | Compositions against protozoal diseases | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | ALDH1A1 2937/4885CYP1A2 2206/4885CYP2D6 453/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2174/4885CYP1A2 1810/4885CYP2D6 953/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | ALDH1A1 3977/4885CYP1A2 852/4885CYP2D6 239/4885 |
| US-20120121661-A1 | DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY | PHOSPHO1, CD44, SELP | ALDH1A1 2513/4885CYP1A2 3202/4885CYP2D6 1273/4885 |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | MCOLN1, PYM1, MCOLN2 | ALDH1A1 2641/4885CYP1A2 1463/4885CYP2D6 400/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | ALDH1A1 2230/4885CYP1A2 1668/4885CYP2D6 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.